Anastrozole
Product Images NDC 42254-161

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 42254-161). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure For Anastrozole (D4f43676 0746 4765 9689 3f1e3075fa6a 01)

Chemical structure of Anastrozole, depicting its molecular framework with aromatic rings and nitrile groups consistent with its known chemical composition.*

FDA Label Image

Figure 1 (D4f43676 0746 4765 9689 3f1e3075fa6a 02)

A line graph comparing disease-free survival over 0 to 80 months between two randomized treatments: anastrozole (dashed line) and tamoxifen (solid line). The y-axis represents the proportion of patients alive and disease-free, ranging from 0.0 to 1.0. Below the graph is a table showing the number of patients at risk for each treatment over time.*

FDA Label Image

Figure 2 (D4f43676 0746 4765 9689 3f1e3075fa6a 03)

A line graph depicting disease-free survival over time in months for two randomized treatments: anastrozole and tamoxifen. The vertical axis represents the proportion alive and disease-free, while the horizontal axis shows disease-free survival time in months, ranging from 0 to 80. Below the graph, a table indicates the number of patients at risk for each treatment over selected time points.*

FDA Label Image

Figure 3 (D4f43676 0746 4765 9689 3f1e3075fa6a 04)

A Kaplan-Meier curve chart illustrating time to progression in months for two randomized treatments: Anastrozole and Tamoxifen. The y-axis represents the proportion of patients not progressing, while the x-axis shows time in months. The chart compares progression rates between the two treatments over a 32-month period with patient risk counts at various time points.*

FDA Label Image

Figure 4 (D4f43676 0746 4765 9689 3f1e3075fa6a 05)

A Kaplan-Meier survival curve chart comparing the proportion not progressed over time in months for two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressed. The chart includes numbers at risk for both treatments at specified time intervals.*

FDA Label Image

Anastrozole 1mg (D4f43676 0746 4765 9689 3f1e3075fa6a 06)

Anastrozole 1 mg tablets label from Rebel Distributors Corp with NDC 42254-161-30. The label states each white round biconvex tablet contains 1 mg of Anastrozole USP, with no score and imprint code 'AHI'. Distributed by Physician Partner, Thousand Oaks, CA. Manufactured by Intas Pharmaceuticals Limited, India. Provides storage instructions and caution to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.